These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30522890)

  • 1. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.
    Glassman PM; Balthasar JP
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
    Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
    Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins.
    Wong H; Chow TW
    J Pharm Sci; 2017 Sep; 106(9):2270-2275. PubMed ID: 28392453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
    Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications.
    Ferl GZ; Theil FP; Wong H
    Biopharm Drug Dispos; 2016 Mar; 37(2):75-92. PubMed ID: 26461173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: Opportunities and challenges.
    Fairman K; Li M; Ning B; Lumen A
    Biochem Pharmacol; 2021 Jul; 189():114468. PubMed ID: 33577889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
    Hu S; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A translational platform PBPK model for antibody disposition in the brain.
    Chang HY; Wu S; Meno-Tetang G; Shah DK
    J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
    Glassman PM; Chen Y; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
    Varkhede N; Forrest ML
    J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.
    Polli JR; Engler FA; Balthasar JP
    J Pharm Sci; 2019 Jan; 108(1):674-691. PubMed ID: 30321546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies.
    Hu L; Hansen RJ
    J Pharm Sci; 2013 Sep; 102(9):2898-908. PubMed ID: 23508847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Another string to your bow: machine learning prediction of the pharmacokinetic properties of small molecules.
    Bassani D; Parrott NJ; Manevski N; Zhang JD
    Expert Opin Drug Discov; 2024 Jun; 19(6):683-698. PubMed ID: 38727016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
    Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
    MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens.
    Glassman PM; Balthasar JP
    MAbs; 2017; 9(2):297-306. PubMed ID: 27892793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs.
    Munir A; Azam S; Fazal S; Bhatti AI
    J Theor Biol; 2018 Aug; 451():1-9. PubMed ID: 29704489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.